425: BioCryst to Acquire Astria, Expanding HAE Portfolio

BioCryst Pharmaceuticals will acquire Astria Therapeutics for approximately $920 million in equity value, adding late-stage HAE therapy navenibart and strengthening its rare disease pipeline.

Summary

• BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) will acquire Astria Therapeutics, Inc. (Nasdaq: ATXS) for an implied value of $13.00 per Astria share, totaling approximately $920 million in aggregate equity value and $700 million in enterprise value.
• The consideration per Astria share consists of $8.55 in cash and 0.59 shares of BioCryst common stock.
• This represents a premium of approximately 53% over Astria's closing share price on October 13, 2025, and 71% over Astria's 20-day VWAP as of October 13, 2025.
• Astria's lead product candidate, navenibart (formerly STAR-0215), an injectable, long-acting plasma kallikrein inhibitor for hereditary angioedema (HAE) prophylaxis, is in Phase 3 clinical development.
• BioCryst will also acquire Astria's early-stage program for atopic dermatitis, STAR-0310, and plans to seek strategic alternatives for this asset.
• Astria stockholders are expected to own approximately 15% of the proforma equity in the combined company based on basic shares outstanding.
• The merger was unanimously approved by the Boards of Directors of both BioCryst and Astria.
• Certain Astria stockholders, including directors, executive officers, and affiliates of Perceptive Advisors L.L.C., have entered into voting and support agreements for the transaction.
• Upon consummation of the merger, Astria Common Stock will be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934.
• Astria Stock Options with an exercise price less than $13.00 per share will fully vest and be canceled in exchange for a cash payment equal to the product of the number of shares and the excess of $13.00 over the exercise price. Options with an exercise price equal to or greater than $13.00 will be canceled for no consideration.
• Astria Pre-Funded Warrants will be converted into the right to receive the Merger Consideration.
• Astria Common Warrants will continue to be outstanding but become exercisable for the Merger Consideration, or holders may elect to receive cash equal to their Black Scholes Value.

Sentiment

Score: 8

Explanation: The filing outlines a strategically sound acquisition that significantly enhances BioCryst's market position in HAE with a promising late-stage asset, offering substantial premiums to Astria shareholders and projecting strong future financial performance for the combined entity. While new debt is incurred, the overall strategic fit and growth prospects are highly positive.

Positives

• The transaction expands BioCryst's portfolio with navenibart, a late-stage, rare disease product candidate for HAE, which has the potential to be a leading injectable treatment.
• Navenibart's highly differentiated every 3and 6-month administration schedule could offer significant improvements over existing injectable options and address key unmet needs in the HAE patient community.
• Earlier clinical trials for navenibart demonstrated strong efficacy and a favorable safety and tolerability profile.
• BioCryst's established commercialization infrastructure and deep expertise in HAE are expected to maximize navenibart's reach and accelerate its launch.
• The combined portfolio will include both a leading oral (Orladeyo) and a potentially best-in-class injectable (navenibart) therapy for HAE, offering optimal choices for individualized patient care.
• The acquisition has the potential to extend BioCryst's runway for double-digit revenue growth through the next decade.
• BioCryst anticipates remaining profitable (non-GAAP) and cash flow positive post-transaction.
• The transaction is expected to be significantly accretive to operating profit (non-GAAP) in the first full year of navenibart's anticipated launch, due to substantial operating synergies.
• Astria stockholders receive a compelling outcome, including cash for their shares at closing and continued ownership in BioCryst, with a significant premium over recent trading prices.
• Jill C. Milne, Astria's CEO, will join the BioCryst board of directors upon closing, bringing valuable expertise.

Negatives

• BioCryst expects to incur significant indebtedness in connection with the transaction, requiring sufficient cash flows to service and repay this debt.
• There is a possibility that the anticipated benefits of the Merger, including synergies, may not be realized when expected or at all, particularly due to integration challenges or competitive factors.
• The transaction may be more expensive to complete than initially anticipated.
• The merger could divert management's attention from ongoing business operations and opportunities.
• Potential adverse reactions or changes to business or employee relationships may arise from the announcement or completion of the transaction.
• The issuance of BioCryst common stock in the Merger carries a potential dilutive effect for existing BioCryst shareholders.
• Risks exist regarding government actions, pricing decisions, and regulatory approvals for navenibart, which may not align with BioCryst's current expectations or timelines.
• The sustainability of profitability and positive cash flow, and anticipated cash balance, may not meet management's expectations.
• Actual financial results may not be consistent with expectations, including revenue, operating expenses, and cash usage.
• Ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not yield positive results, and early trial outcomes may not predict later success.

Risks

• The occurrence of any event, change, or other circumstances that could give rise to the right of one or both parties to terminate the Merger Agreement.
• The outcome of any legal proceedings that may be instituted against BioCryst or Astria.
• Failure to obtain necessary regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the Merger) and Astria stockholder approval, or to satisfy any of the other conditions to the Merger on a timely basis or at all.
• The possibility that the anticipated benefits of the Merger, including anticipated synergies, are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where BioCryst and Astria do business.
• The significant indebtedness BioCryst expects to incur in connection with the Transaction and the need to generate sufficient cash flows to service and repay such debt.
• The possibility that the Merger may be more expensive to complete than anticipated.
• Diversion of management's attention from ongoing business operations and opportunities.
• Potential adverse reactions or changes to business or employee relationships, including those resulting from the announcement or completion of the Merger.
• Risks relating to the potential dilutive effect of shares of BioCryst common stock to be issued in the Merger.
• BioCryst's HAE portfolio and revenue growth expectations may not be achieved due to, among other risks, risks related to government actions, including that decisions and other actions, including as they relate to pricing for navenibart, may not be taken when expected or at all, or that the outcomes of such decisions and other actions may not be in line with BioCryst's current expectations.
• Risks that the FDA, or other applicable regulatory agency, may not provide regulatory clearances or approval for navenibart on the expected timeline or at all, may impose certain restrictions, warnings, or other requirements on products and product candidates (including navenibart), may impose a clinical hold with respect to navenibart, or may withhold, delay, or withdraw market approval for products and product candidates (including navenibart), and risks that navenibart, if approved, may not achieve market acceptance.
• Sustainability of profitability and positive cash flow, and anticipated cash balance, may not meet management's expectations.
• Statements and projections regarding financial guidance and goals and the attainment of such goals may differ from actual results based on market factors and BioCryst's ability to execute its operational and budget plans.
• Actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges.
• Ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials.

Future Outlook

BioCryst anticipates continued profitability (non-GAAP) and positive cash flow post-transaction. The addition of navenibart is expected to extend BioCryst's runway for double-digit revenue growth through the next decade and be significantly accretive to operating profit (non-GAAP) in the first full year of navenibart's anticipated launch. Top-line data from navenibart's pivotal ALPHA-ORBIT trial is expected in early 2027. BioCryst plans to seek strategic alternatives for Astria's early-stage program, STAR-0310.

Management Comments

• "We believe this transaction gives BioCryst a perfect second product candidate that fits seamlessly with our HAE core competency and enables us to build out a comprehensive portfolio that could offer the most patient-friendly option, regardless of administration preference." Jon Stonehouse, Chief Executive Officer of BioCryst.
• "Navenibart can emerge as the injectable of choice for patients seeking infrequent, pain-free dosing, strong attack control, and a mechanism of action they know and understand." Jon Stonehouse, Chief Executive Officer of BioCryst.
• "With our leading product, Orladeyo, and navenibart's potentially best-in-class profile, we will be well-positioned to drive sustainable growth and profitability while optimally serving the HAE patient community." Jon Stonehouse, Chief Executive Officer of BioCryst.
• "We are thrilled to have navenibart become an integral part of BioCryst's HAE portfolio, advancing our shared mission of empowering patients to live beyond the limitations of their disease." Jill C. Milne, Ph.D., Chief Executive Officer of Astria Therapeutics.
• "We have great confidence in BioCryst's proven expertise and ability to successfully bring navenibart to patients who need better options for managing HAE and improving their quality of life." Jill C. Milne, Ph.D., Chief Executive Officer of Astria Therapeutics.
• "Importantly, this transaction represents a compelling outcome for Astria stockholders, providing cash for their shares at closing as well as continued ownership of BioCryst." Jill C. Milne, Ph.D., Chief Executive Officer of Astria Therapeutics.
• "I am incredibly proud of our talented Astria team, whose dedication and hard work have brought us to this important milestone." Jill C. Milne, Ph.D., Chief Executive Officer of Astria Therapeutics.

Industry Context

This acquisition significantly strengthens BioCryst's position in the Hereditary Angioedema (HAE) market, a rare disease area where it already commercializes ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor. By adding navenibart, an injectable, long-acting plasma kallikrein inhibitor, BioCryst is poised to offer a comprehensive HAE portfolio that caters to diverse patient preferences (oral vs. infrequent injectable). The move positions BioCryst to capture a larger share of the HAE prophylaxis market, which includes over 5,000 patients currently treated with injectable options, by offering a differentiated and potentially best-in-class therapy.

Comparison to Industry Standards

• Navenibart's highly differentiated every 3and 6-month administration schedule could offer significant improvements over existing injectable options, addressing key unmet needs in the HAE patient community.
• Phase 1b/2 data for navenibart suggest its potential to match or exceed the efficacy of marketed and developmental therapies, such as Andem Bry, Takhzyro, and Donidalorsen, while substantially reducing treatment burden.
• The citrate-free, high-concentration formulation of navenibart, delivered via autoinjector, is designed for pain-free administration, potentially offering a superior patient experience compared to other injectable HAE treatments.

Management Changes

Corporate Governance

Legal Proceedings

• The 'Cautionary Statement Regarding Forward-Looking Statements' section identifies 'the outcome of any legal proceedings that may be instituted against BioCryst or Astria' as a risk factor that could cause actual results to differ materially from anticipated results. No specific pending or threatened material legal proceedings are detailed as factual events in the filing.

Related Party Transactions

• Affiliates of Perceptive Advisors L.L.C., Astria's largest stockholder as of October 13, 2025, entered into voting and support agreements with BioCryst in connection with the Merger Agreement.

Stakeholder Impact

• **Shareholders (Astria):** Will receive a significant premium (53% over closing price, 71% over VWAP) for their shares, a mix of cash and BioCryst stock, providing immediate value and continued equity participation in a larger, diversified company.
• **Shareholders (BioCryst):** Face potential dilution from the issuance of new shares but gain a late-stage, potentially best-in-class asset that is expected to drive long-term revenue growth and operating profit accretion.
• **Employees (Astria):** The filing mentions potential adverse reactions or changes to employee relationships as a risk. However, it also states that BioCryst will provide Continuing Employees with comparable base salary, bonus opportunities, and severance benefits for at least one year post-merger, and recognize prior service for vesting and eligibility in Parent Benefit Plans.
• **Customers/Patients (HAE):** The merger is expected to expand patient options in HAE by combining BioCryst's oral therapy (Orladeyo) with Astria's long-acting injectable (navenibart), potentially offering more individualized care and addressing unmet needs.
• **Management (Astria):** Astria's CEO, Jill C. Milne, will join the BioCryst board, indicating a degree of continuity and integration at the leadership level. Other officers and directors are expected to resign upon request.
• **Creditors:** BioCryst will incur significant indebtedness through a $550 million credit facility to fund the cash portion of the acquisition, which will impact its debt profile and cash flow obligations.

Next Steps

• Astria stockholders must vote to approve the adoption of the Merger Agreement.
• BioCryst will file a registration statement on Form S-4 with the SEC, which will include a proxy statement for Astria and a prospectus for BioCryst.
• The Form S-4 must be declared effective under the Securities Act.
• The shares of BioCryst Common Stock to be issued in the Merger must be approved for listing on Nasdaq.
• The Merger is expected to close in the first quarter of 2026, pending customary regulatory approvals and Astria stockholder approval.
• Top-line data from navenibart's pivotal ALPHA-ORBIT Phase 3 trial is expected in early 2027.
• The ORBIT-EXPANSE long-term Phase 3 trial is actively enrolling ALPHA-ORBIT roll-over participants.
• CMC (Chemistry, Manufacturing, and Controls) and device work for navenibart (auto-injector and pre-filled syringe options) remains on track.
• BioCryst plans to seek strategic alternatives for Astria's early-stage program, STAR-0310.

Key Dates

Recommendation

The acquisition of Astria Therapeutics by BioCryst Pharmaceuticals is a highly strategic move that significantly enhances BioCryst's position in the growing Hereditary Angioedema (HAE) market. Navenibart, Astria's lead asset, is a late-stage, potentially best-in-class injectable therapy that complements BioCryst's existing oral HAE product, Orladeyo. This creates a comprehensive portfolio addressing diverse patient needs and is expected to drive double-digit revenue growth for BioCryst through the next decade, with the transaction projected to be accretive to operating profit. While the deal involves new debt and integration risks, the substantial premium offered to Astria shareholders and the clear strategic rationale for BioCryst suggest a strong long-term value proposition for the combined entity. The market opportunity for navenibart, coupled with BioCryst's proven commercial infrastructure, positions the company for accelerated growth and sustained profitability.

Keywords

BioCryst Pharmaceuticals, Astria Therapeutics, Merger, Acquisition, Hereditary Angioedema, HAE, Navenibart, STAR-0215, Plasma Kallikrein Inhibitor, Rare Disease, Biopharmaceutical, Clinical Development, Phase 3, Orladeyo, STAR-0310, Atopic Dermatitis, Nasdaq, SEC Filing, M&A, Biotechnology, Drug Development, Pharmaceutical